Boston Scientific (NYSE:BSX) Hits New 1-Year Low – Here’s Why

Shares of Boston Scientific Corporation (NYSE:BSX) reached a new 52-week low on Tuesday . The company traded as low as $44.05 and last traded at $44.2980, with a volume of 16759915 shares trading hands. The stock had previously closed at $45.29.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on BSX. Argus raised Boston Scientific to a “strong-buy” rating in a research note on Thursday, February 26th. Royal Bank Of Canada restated an “outperform” rating on shares of Boston Scientific in a report on Thursday, May 28th. Daiwa Securities Group lowered Boston Scientific from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 29th. Bank of America lowered their price target on Boston Scientific from $105.00 to $68.00 and set a “buy” rating for the company in a research note on Monday, May 18th. Finally, Weiss Ratings downgraded shares of Boston Scientific from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday, May 13th. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Boston Scientific presently has a consensus rating of “Moderate Buy” and an average price target of $85.08.

Boston Scientific Price Performance

The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42. The company has a fifty day moving average price of $54.37 and a two-hundred day moving average price of $72.44. The firm has a market cap of $65.84 billion, a P/E ratio of 18.53, a PEG ratio of 0.87 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. The firm had revenue of $5.20 billion during the quarter, compared to analyst estimates of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The company’s revenue for the quarter was up 11.6% compared to the same quarter last year. During the same period in the prior year, the business earned $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Equities analysts anticipate that Boston Scientific Corporation will post 3.36 earnings per share for the current year.

Boston Scientific announced that its Board of Directors has initiated a share buyback plan on Monday, May 18th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s board believes its shares are undervalued.

Insider Buying and Selling at Boston Scientific

In other news, Director David C. Habiger purchased 2,250 shares of Boston Scientific stock in a transaction on Wednesday, May 20th. The stock was purchased at an average price of $55.92 per share, with a total value of $125,820.00. Following the transaction, the director directly owned 13,878 shares in the company, valued at $776,057.76. The trade was a 19.35% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Cheryl Pegus purchased 1,770 shares of the firm’s stock in a transaction dated Wednesday, May 20th. The shares were acquired at an average cost of $56.49 per share, with a total value of $99,987.30. Following the completion of the purchase, the director directly owned 1,770 shares in the company, valued at approximately $99,987.30. This represents a ? increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last quarter, insiders have bought 9,800 shares of company stock worth $554,012. Corporate insiders own 0.34% of the company’s stock.

Institutional Investors Weigh In On Boston Scientific

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its holdings in shares of Boston Scientific by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 139,685,997 shares of the medical equipment provider’s stock valued at $13,319,060,000 after acquiring an additional 1,436,550 shares in the last quarter. State Street Corp raised its holdings in Boston Scientific by 1.4% during the fourth quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider’s stock worth $6,278,422,000 after acquiring an additional 920,495 shares in the last quarter. Capital World Investors boosted its position in Boston Scientific by 1.9% during the fourth quarter. Capital World Investors now owns 27,151,575 shares of the medical equipment provider’s stock valued at $2,588,953,000 after purchasing an additional 502,627 shares during the last quarter. Norges Bank acquired a new position in Boston Scientific during the fourth quarter valued at approximately $2,199,395,000. Finally, Morgan Stanley grew its stake in Boston Scientific by 10.8% in the fourth quarter. Morgan Stanley now owns 22,960,556 shares of the medical equipment provider’s stock valued at $2,189,289,000 after purchasing an additional 2,246,308 shares in the last quarter. 89.07% of the stock is owned by institutional investors.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.